Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure.
Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F. Radauceanu A, et al. Among authors: zannad f. J Card Fail. 2008 Aug;14(6):467-74. doi: 10.1016/j.cardfail.2008.02.014. Epub 2008 May 27. J Card Fail. 2008. PMID: 18672194 Clinical Trial.
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Mann DL, et al. Among authors: zannad f. Circulation. 2004 Apr 6;109(13):1594-602. doi: 10.1161/01.CIR.0000124490.27666.B2. Epub 2004 Mar 15. Circulation. 2004. PMID: 15023878 Clinical Trial.
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Gheorghiade M, et al. Among authors: zannad f. J Card Fail. 2005 May;11(4):260-9. doi: 10.1016/j.cardfail.2005.03.009. J Card Fail. 2005. PMID: 15880334 Clinical Trial.
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J; EPHESUS Investigators. Pitt B, et al. Among authors: zannad f. J Am Coll Cardiol. 2005 Aug 2;46(3):425-31. doi: 10.1016/j.jacc.2005.04.038. J Am Coll Cardiol. 2005. PMID: 16053953 Free article. Clinical Trial.
Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression.
Seguin-Devaux C, Hanriot D, Dailloux M, Latger-Cannard V, Zannad F, Mertes PM, Longrois D, Devaux Y. Seguin-Devaux C, et al. Among authors: zannad f. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):67-76. doi: 10.1016/j.mce.2005.10.006. Epub 2005 Nov 23. Mol Cell Endocrinol. 2005. PMID: 16309824
In sharp contrast to our previous observations that atRA supplementation enhances IFN-gamma expression and NOS2 pathway activation in LPS-challenged rats [Devaux, Y., Grosjean, S., Seguin, C., David, C., Dousset, B., Zannad, F., Meistelman, C., de Talance, N., Merte …
In sharp contrast to our previous observations that atRA supplementation enhances IFN-gamma expression and NOS2 pathway activation in LPS-ch …
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%.
Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H; EPHESUS Investigators. Pitt B, et al. Among authors: zannad f. Eur J Heart Fail. 2006 May;8(3):295-301. doi: 10.1016/j.ejheart.2005.11.008. Epub 2006 Feb 28. Eur J Heart Fail. 2006. PMID: 16504579 Free article. Clinical Trial.
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Køber L, et al. Among authors: zannad f. Eur J Heart Fail. 2006 Oct;8(6):591-8. doi: 10.1016/j.ejheart.2005.11.007. Epub 2006 Feb 28. Eur J Heart Fail. 2006. PMID: 16507350 Free article. Clinical Trial.
Left bundle branch block as a risk factor for progression to heart failure.
Zannad F, Huvelle E, Dickstein K, van Veldhuisen DJ, Stellbrink C, Køber L, Cazeau S, Ritter P, Maggioni AP, Ferrari R, Lechat P. Zannad F, et al. Eur J Heart Fail. 2007 Jan;9(1):7-14. doi: 10.1016/j.ejheart.2006.04.011. Epub 2006 Aug 4. Eur J Heart Fail. 2007. PMID: 16890486 Free article. Review.
1,202 results